In accordance with the latest scientific findings, we are updating our somatic tumor panel. The total number of genes on this panel is now 710, up from 649. The panel now includes mutational load analysis of the tumor and also supports the examination of leukemia and lymphoma.
The current update was designed to enable personalized therapy decisions, determined by an interdisciplinary tumor board, addressing solid tumors, leukemia and lymphoma. We’ve added additional genes that, according to the latest scientific findings, are linked to the development, growth, disease outlook, drug metabolism, and tumor therapy outcome. The examination of selected translocations is now performed in 29 genes.
In addition to the reporting of these treatment-relevant gene changes, we are also expanding our medical reports by reporting the mutation load of the tumor. Data increasingly suggests that tumors with very high mutation load have increased numbers of neo-antigens on the cell surface, and may therefore respond particularly well to immunotherapeutic approaches, such as checkpoint inhibitors.
In the context of genetic counseling, it is also possible to carry out tumor diagnostics by performing a liquid biopsy (blood test). If you would prefer this option, please arrange a personal appointment.
In parallel to these changes, we have also updated our panel for the diagnosis of hereditary tumor diseases by expanding the number of analyzed genes from 110 to a total of 124. Genes associated with increased tumor risk in gastric carcinoma, Cowden’s syndrome, as well as tumors of the central nervous system have been added. Furthermore, several indications already included in the panel have been extended by the addition of the new genes.
CeGaT expands tumor diagnostics services by introducing selective BRCA1/2 testing for ovarian cancer.
Olaparib (LynparzaTM), a promising drug for the treatment of recurrent, platinum-sensitive, high-grade serous ovarian carcinoma, was approved by the European Medicines Agency (EMA) in 2015. One requirement for the therapy with Olaparib is the detection of a mutation in the genes BRCA1 or BRCA2.
Both genes have always been included in our Somatic Tumor Panel; however, due to their importance for the prescription of Olaparib, CeGaT has decided to offer a test specific for BRCA1 and BRCA2. Using this test, mutations in these genes will be detected quickly and directly, saving time when critical therapy decisions need to be made.
For further information on BRCA1/2 testing, please visit the section for ovarian cancer.
Research in the field of tumor genetics advanced greatly in recent years. In order to incorporate the latest developments and findings in our Tumor Diagnostics services, the Somatic Tumor Panel has been completely revised and expanded from 551 to 649 genes.
With the updated Somatic Tumor Panel it is now also possible to detect translocations in 28 selected genes. Translocations (such as ALK and ROS1 fusions in lung cancer) play an important role in many cancers, enabling a highly targeted treatment.
For the list of genes and further information please visit the Somatic Tumor Panel section of our website.
CeGaT’s innovative approach to Tumor Diagnostics has been recognized with the Industry Award 2015 for the Biotechnology category.
Winners were chosen for each of 14 categories, and CeGaT’s somatic Tumor Panel won the Biotechnology category, garnering a trophy and certificate. The independent jury of the Industry Award 2015 consisted of experts including professors, scientists, industry representatives and journalists. Products and solutions were evaluated on specific criteria, such as the level of innovation (novelty, product maturity, and future orientation), benefits (recognizable benefit, impact on profitability, improved efficiency) and suitability for a mid-sized company (relevance, practicality, implementation). “Receiving the Industry Award 1015 for the establishment of our Tumor Diagnostics for patient care confirms our work and shows us that we are on the right track,” said managing director Dr. Saskia Biskup, very happy with the honor.
CeGaT’s somatic Tumor Panel generates a comprehensive genetic fingerprint of a tumor. Sequence data from a patient’s tumor is compared to sequence data from the patient’s own normal tissue, which is an essential step towards personalized medicine. In approximately 80% of cases, sequence changes detected between the tumor and normal tissue have treatment-related consequences, which provides the attending oncologist with essential information in developing an optimal therapy for the patient.